
    
      The Lutonix® 035 Drug Coated Balloon PTA Catheter (Lutonix® Catheter) has been approved by
      the Food and Drug Administration (P130024) for percutaneous transluminal angioplasty, after
      appropriate vessel preparation of de novo, restenotic, or in-stent restenotic lesions up to
      300 mm in length in native superficial femoral or popliteal arteries with reference vessel
      diameters of 4-7 mm. The purpose of this post-approval study is to assess the safety and
      effectiveness of the Lutonix® Catheter in the US female population. This study will enroll
      approximately 165 female patients at a minimum of 10 US centers and a maximum of 25.
    
  